Literature DB >> 15721440

Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.

Ronald D Hardy1, Jeffrey G Bell, Charles J Nicely, Gary C Reid.   

Abstract

BACKGROUND: Granulosa cell tumors of the ovary are rare, primarily treated surgically. In advanced or recurrent disease, data are inconclusive regarding the benefit of either primary or adjuvant chemotherapy. Hormonal therapy has been suggested as an alternative treatment. CASE: Our patient had three recurrences of estrogen receptor negative and progesterone receptor positive GCT, the first two treated by surgery with or without adjuvant chemotherapy. For the third recurrence, the patient received alternating biweekly cycles of megestrol and tamoxifen. Computed tomography showed stable disease at 6 months, partial response at 18 months, and complete response at 22 months. The patient continues on hormonal therapy and has been disease-free for 5 years.
CONCLUSION: This study and others suggest that hormonal therapy may provide another option for treating these relatively rare tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721440     DOI: 10.1016/j.ygyno.2004.10.042

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  The role of systemic chemotherapy in the management of granulosa cell tumors.

Authors:  Jane L Meisel; David M Hyman; Anjali Jotwani; Qin Zhou; Nadeem R Abu-Rustum; Alexia Iasonos; Malcolm C Pike; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2014-12-26       Impact factor: 5.482

Review 2.  Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review.

Authors:  Geertruid J Brink; Jolijn W Groeneweg; Lotty Hooft; Ronald P Zweemer; Petronella O Witteveen
Journal:  Cancers (Basel)       Date:  2022-06-17       Impact factor: 6.575

Review 3.  Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.

Authors:  Dirkje W Sommeijer; Katrin M Sjoquist; Michael Friedlander
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 4.  Recent advances in granulosa cell tumor ovary: a review.

Authors:  Vijaykumar Dehannathparambil Kottarathil; Michelle Aline Antony; Indu R Nair; Keechilat Pavithran
Journal:  Indian J Surg Oncol       Date:  2012-12-07

5.  A late recurring and easily forgotten tumor: ovarian granulosa cell tumor.

Authors:  Yi-Chan Chen; Liang-Che Chang; Ruey-Shyang Soong
Journal:  World J Surg Oncol       Date:  2012-05-16       Impact factor: 2.754

6.  Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.

Authors:  Florian Viehweger; Lisa-Marie Tinger; David Dum; Natalia Gorbokon; Anne Menz; Ria Uhlig; Franziska Büscheck; Andreas M Luebke; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Christoph Fraune; Patrick Lebok; Sören Weidemann; Maximilian Lennartz; Frank Jacobsen; Till S Clauditz; Rainer Krech; Till Krech; Andreas H Marx; Ronald Simon; Eike Burandt; Stefan Steurer; Guido Sauter; Sarah Minner; Christian Bernreuther
Journal:  Anal Cell Pathol (Amst)       Date:  2022-08-08       Impact factor: 4.133

7.  Nearly 30 Years of Treatment for Recurrent Granulosa Cell Tumor of the Ovary: A Case Report and Review of the Literature.

Authors:  Deanna Teoh; Ralph Freedman; Pamela T Soliman
Journal:  Case Rep Oncol       Date:  2010-01-13

8.  The multifaceted granulosa cell tumours-myths and realities: a review.

Authors:  Rani Kanthan; Jenna-Lynn Senger; Selliah Kanthan
Journal:  ISRN Obstet Gynecol       Date:  2012-09-13

9.  The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors.

Authors:  Sabine Heublein; Doris Mayr; Klaus Friese; Maria Cristina Jarrin-Franco; Miriam Lenhard; Artur Mayerhofer; Udo Jeschke
Journal:  Int J Mol Sci       Date:  2014-08-27       Impact factor: 5.923

10.  GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report.

Authors:  Yuan Zhuang; Shushan Zhang; Yao Liu; Hua Yang
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.